Last reviewed · How we verify
NCT04677075
New Formula to Predict the Need for Reconstructive Coverage Following Mastectomy
trial testing mastectomy in Breast Neoplasms in 74 participants. Completed in 15 September 2023.
15 August 2023
Quick facts
| Lead sponsor | Zagazig University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 74 |
| Start date | 15 August 2020 |
| Primary completion | 15 August 2023 |
| Estimated completion | 15 September 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- mastectomy
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
Sponsor
Zagazig University
Who can join
Eligibility, female only, with Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mastectomy is a cornerstone operative procedure in breast cancer treatment leaving a raw area behind with possibility of failure of primary closure sometimes with unavailability of facilities of reconstruction. This opened the door for this research to find a formula to predict the need of reconstruction
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04677075
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Other Zagazig University trials
Trials by the same sponsor.
- NCT07423676 — Comparison Between Two Drugs in Sedation of Upper GI Endoscopy · not yet recruiting
- NCT07418307 — Comparison Between Combined Biceps Femoris Short Head Block and Adductor Canal Block Versus Genicular Nerve Block · NA · not yet recruiting
- NCT07435025 — Surgery for Obstructed Gastric Carcinoma · NA · active not recruiting
- NCT07330375 — Effect of Intravenous Dexmedetomidine and Ketamine on Post-Operative Analgesia · Phase 3 · not yet recruiting
- NCT07309731 — Impact OF Cooled Versus Thermal Radiofrequency Denervation In Management Of Chronic Lumber Facet Joint Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04677075 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zagazig University
- Last refreshed: 20 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04677075.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing